The United Kingdom and the United States have hammered out a key bilateral deal that will maintain no import taxes on British medicine products entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the NHS. This commitment guarantees that duties on these crucial exports will remain at nothing for a timeframe of three years.
This agreement is in response to earlier statements to dramatically increase tariffs on branded pharmaceutical imports, with figures floated as high as one hundred percent.
"This deal with the UK bolsters the international landscape for new treatments and introduces long-overdue balance to American-British drug exports," a statement noted.
Commercial Impact
Medicines constitute one of the the United Kingdom's largest exports to the United States, which is easily the primary destination for large companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to last September, the UK shipped drugs valued at over eleven billion pounds to the US. This value accounted for 17.4% of total UK exports in that timeframe.
"This guarantee secures employment, stimulates investment and facilitates the UK to emerge as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to increase overall public funding on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The sum manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. Previously, rebates exceeded twenty percent.
Industry Background
The pact takes place against a long-running dispute between the sector and the British authorities over spending levels and approval rates.
The disagreement were heightened by claims that US patients were charged a premium for the equivalent treatments than patients in the other developed nations.
Recently, several major pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar funding commitments have been directed toward American operations.
The Science Minister publicly accepted that the NHS must invest a greater share on drugs, noting that its spending on drugs had declined as a percentage of its total funding over the last ten years.
